Download PDF
Semin Liver Dis 2015; 35(03): 262-269
DOI: 10.1055/s-0035-1562946
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Gut Microbiota and Nonalcoholic Fatty Liver Disease

Eamonn M. Quigley
1   Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas
,
Howard P. Monsour
1   Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
17 September 2015 (online)

    Permissions and Reprints

Abstract

With the recognition of the various metabolic functions of the gut microbiome and of its putative role in obesity, an investigation of the contribution of the bacterial populations of the gastrointestinal tract to the metabolic syndrome and its hepatic manifestation—nonalcoholic liver disease (NAFLD)—became inevitable. Furthermore, the central role of an altered microbiome in the precipitation of infectious and noninfectious complications of liver disease was described decades ago. The contribution of the microbiome to the pathogenesis of NAFLD has been extensively studied in animal models. Convincing evidence for a central role for an altered microbiome (through multiple mechanisms), coupled with such phenomena as impaired gut barrier function and an aberrant host immune response, has been amply demonstrated. The accumulation of a similar level of evidence from human studies has proven more challenging; however, incriminating data accumulate. Although animal studies have demonstrated the benefits of interventions that modulate the microbiome and of probiotics, in particular, in reducing steatosis and preventing progression to steatohepatitis, data in man are scanty and high-quality clinical trials of probiotics and other strategies are needed.

Keywords

microbiome - nonalcoholic fatty liver disease - gut barrier - steatosis - metabolic syndrome - probiotics
 

  • References

  • 1 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146 (6) 1513-1524
    CrossrefPubMedGoogle Scholar
  • 2 Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7 (12) 691-701
    CrossrefPubMedGoogle Scholar
  • 3 Fraher MH, O'Toole PW, Quigley EMM. Techniques used to characterise the intestinal microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012; 9: 312-322
    CrossrefPubMedGoogle Scholar
  • 4 Nicholson JK, Holmes E, Kinross J , et al. Host-gut microbiota metabolic interactions. Science 2012; 336 (6086) 1262-1267
    CrossrefPubMedGoogle Scholar
  • 5 Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13 (4) 260-270
    CrossrefPubMedGoogle Scholar
  • 6 Miyake Y, Yamamoto K. Role of gut microbiota in liver diseases. Hepatol Res 2013; 43 (2) 139-146
    CrossrefPubMedGoogle Scholar
  • 7 Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014; 59 (1) 328-339
    CrossrefPubMedGoogle Scholar
  • 8 Janssen AW, Kersten S. The role of the gut microbiota in metabolic health. FASEB J 2015; 29: 3111-3123
    CrossrefPubMedGoogle Scholar
  • 9 Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol 2013; 58 (5) 1020-1027
    CrossrefPubMedGoogle Scholar
  • 10 Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13 (10) 701-712
    CrossrefPubMedGoogle Scholar
  • 11 Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest 2015; 125 (3) 926-938
    CrossrefPubMedGoogle Scholar
  • 12 Hildebrandt MA, Hoffmann C, Sherrill-Mix SA , et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009; 137 (5) 1716-24.e1 , 2
    CrossrefPubMedGoogle Scholar
  • 13 Moschen AR, Wieser V, Tilg H. Dietary factors: major regulators of the gut's microbiota. Gut Liver 2012; 6 (4) 411-416
    CrossrefPubMedGoogle Scholar
  • 14 Clarke SF, Murphy EF, Nilaweera K , et al. The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes 2012; 3 (3) 186-202
    CrossrefPubMedGoogle Scholar
  • 15 Claesson MJ, Jeffery IB, Conde S , et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488 (7410) 178-184
    CrossrefPubMedGoogle Scholar
  • 16 Hacquard S, Garrido-Oter R, González A , et al. Microbiota and Host Nutrition across Plant and Animal Kingdoms. Cell Host Microbe 2015; 17 (5) 603-616
    CrossrefPubMedGoogle Scholar
  • 17 Doré J, Blottière H. The influence of diet on the gut microbiota and its consequences for health. Curr Opin Biotechnol 2015; 32: 195-199
    CrossrefPubMedGoogle Scholar
  • 18 Yatsunenko T, Rey FE, Manary MJ , et al. Human gut microbiome viewed across age and geography. Nature 2012; 486 (7402) 222-227
    PubMedGoogle Scholar
  • 19 Mutlu EA, Gillevet PM, Rangwala H , et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012; 302 (9) G966-G978
    CrossrefPubMedGoogle Scholar
  • 20 Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1 (1) 56-66
    CrossrefPubMedGoogle Scholar
  • 21 Fouhy F, Guinane CM, Hussey S , et al. High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother 2012; 56 (11) 5811-5820
    CrossrefPubMedGoogle Scholar
  • 22 Cox LM, Blaser MJ. Antibiotics in early life and obesity. Nat Rev Endocrinol 2015; 11 (3) 182-190
    PubMedGoogle Scholar
  • 23 Cho I, Yamanishi S, Cox L , et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012; 488 (7413) 621-626
    CrossrefPubMedGoogle Scholar
  • 24 Lobstein T, Jackson-Leach R, Moodie ML , et al. Child and adolescent obesity: part of a bigger picture. Lancet 2015; ;(e-pub ahead of print)
    PubMedGoogle Scholar
  • 25 Nobili V, Alkhouri N, Alisi A , et al. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr 2015; 169 (2) 170-176
    CrossrefPubMedGoogle Scholar
  • 26 Sayin SI, Wahlström A, Felin J , et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17 (2) 225-235
    CrossrefPubMedGoogle Scholar
  • 27 Li F, Jiang C, Krausz KW , et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013; 4: 2384
    CrossrefPubMedGoogle Scholar
  • 28 Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis 2010; 28 (6) 737-744
    CrossrefPubMedGoogle Scholar
  • 29 Quigley EMM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993; 104 (1) 286-301
    CrossrefPubMedGoogle Scholar
  • 30 Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a “leaky gut”?. Clin Rev Allergy Immunol 2009; 36 (1) 40-51
    CrossrefPubMedGoogle Scholar
  • 31 Terjung B, Söhne J, Lechtenberg B , et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010; 59 (6) 808-816
    CrossrefPubMedGoogle Scholar
  • 32 Quigley EM. Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited. Dig Dis Sci 1996; 41 (3) 557-561
    CrossrefPubMedGoogle Scholar
  • 33 Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54 (4) 556-563
    CrossrefPubMedGoogle Scholar
  • 34 Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol 2015; 7 (3) 425-442
    CrossrefPubMedGoogle Scholar
  • 35 Teltschik Z, Wiest R, Beisner J , et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology 2012; 55 (4) 1154-1163
    CrossrefPubMedGoogle Scholar
  • 36 Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48 (2) 206-211
    CrossrefPubMedGoogle Scholar
  • 37 Shanab AA, Scully P, Crosbie O , et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011; 56 (5) 1524-1534
    CrossrefPubMedGoogle Scholar
  • 38 Bajaj JS, Hylemon PB, Ridlon JM , et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303 (6) G675-G685
    CrossrefPubMedGoogle Scholar
  • 39 Qin N, Yang F, Li A , et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513 (7516) 59-64
    CrossrefPubMedGoogle Scholar
  • 40 Bajaj JS, Heuman DM, Hylemon PB , et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (5) 940-947
    CrossrefPubMedGoogle Scholar
  • 41 Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012; 11 (4) 440-449
    PubMedGoogle Scholar
  • 42 Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102 (31) 11070-11075
    CrossrefPubMedGoogle Scholar
  • 43 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444 (7122) 1027-1031
    CrossrefPubMedGoogle Scholar
  • 44 Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol 2009; 587 (Pt 17) 4153-4158
    CrossrefPubMedGoogle Scholar
  • 45 Turnbaugh PJ, Hamady M, Yatsunenko T , et al. A core gut microbiome in obese and lean twins. Nature 2009; 457 (7228) 480-484
    Google Scholar
  • 46 Murphy EF, Cotter PD, Healy S , et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010; 59 (12) 1635-1642
    CrossrefPubMedGoogle Scholar
  • 47 Parks BW, Nam E, Org E , et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab 2013; 17 (1) 141-152
    CrossrefPubMedGoogle Scholar
  • 48 Everard A, Belzer C, Geurts L , et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013; 110 (22) 9066-9071
    CrossrefPubMedGoogle Scholar
  • 49 Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A 2012; 109 (2) 594-599
    CrossrefPubMedGoogle Scholar
  • 50 de Vos WM, Nieuwdorp M. Genomics: A gut prediction. Nature 2013; 498 (7452) 48-49
    CrossrefPubMedGoogle Scholar
  • 51 Karlsson FH, Tremaroli V, Nookaew I , et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498 (7452) 99-103
    CrossrefPubMedGoogle Scholar
  • 52 Zupancic ML, Cantarel BL, Liu Z , et al. Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. PLoS ONE 2012; 7 (8) e43052
    CrossrefPubMedGoogle Scholar
  • 53 Penas-Steinhardt A, Barcos LS, Belforte FS , et al. Functional characterization of TLR4 +3725 G/C polymorphism and association with protection against overweight. PLoS ONE 2012; 7 (12) e50992
    CrossrefPubMedGoogle Scholar
  • 54 Kim K-A, Gu W, Lee I-A, Joh E-H, Kim D-H. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS ONE 2012; 7 (10) e47713
    CrossrefPubMedGoogle Scholar
  • 55 Vijay-Kumar M, Aitken JD, Carvalho FA , et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328 (5975) 228-231
    CrossrefPubMedGoogle Scholar
  • 56 Raman M, Ahmed I, Gillevet PM , et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11 (7) 868-75.e1 , 3
    CrossrefPubMedGoogle Scholar
  • 57 Mouzaki M, Comelli EM, Arendt BM , et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013; 58 (1) 120-127
    CrossrefPubMedGoogle Scholar
  • 58 Zhu L, Baker SS, Gill C , et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57 (2) 601-609
    CrossrefPubMedGoogle Scholar
  • 59 Le Roy T, Llopis M, Lepage P , et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013; 62 (12) 1787-1794
    CrossrefPubMedGoogle Scholar
  • 60 Wong VW-S, Tse C-H, Lam TT-Y , et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis—a longitudinal study. PLoS ONE 2013; 8 (4) e62885
    CrossrefPubMedGoogle Scholar
  • 61 Jiang W, Wu N, Wang X , et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015; 5: 8096
    CrossrefPubMedGoogle Scholar
  • 62 Dumas ME, Barton RH, Toye A , et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006; 103 (33) 12511-12516
    CrossrefPubMedGoogle Scholar
  • 63 Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011; 140 (3) 976-986
    CrossrefPubMedGoogle Scholar
  • 64 Michail S, Lin M, Frey MR , et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 2015; 91 (2) 1-9
    PubMedGoogle Scholar
  • 65 Engstler AJ, Aumiller T, Degen C , et al. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut 2015; ; [Epub ahead of print]
    PubMedGoogle Scholar
  • 66 Henao-Mejia J, Elinav E, Jin C , et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482 (7384) 179-185
    PubMedGoogle Scholar
  • 67 Sawada K, Ohtake T, Hasebe T , et al. Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice. Hepatol Res 2014; 44 (8) 920-934
    CrossrefPubMedGoogle Scholar
  • 68 Wagnerberger S, Spruss A, Kanuri G , et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 2012; 107 (12) 1727-1738
    CrossrefPubMedGoogle Scholar
  • 69 Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (23) 7381-7391
    CrossrefPubMedGoogle Scholar
  • 70 Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 2012; 590 (Pt 3) 447-458
    CrossrefPubMedGoogle Scholar
  • 71 Jiang C, Xie C, Li F , et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015; 125 (1) 386-402
    CrossrefPubMedGoogle Scholar
  • 72 Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009; 27: 147-163
    CrossrefPubMedGoogle Scholar
  • 73 Seo YS, Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol 2012; 18 (4) 337-346
    CrossrefPubMedGoogle Scholar
  • 74 Catalá M, Antón A, Portolés MT. Characterization of the simultaneous binding of Escherichia coli endotoxin to Kupffer and endothelial liver cells by flow cytometry. Cytometry 1999; 36 (2) 123-130
    CrossrefPubMedGoogle Scholar
  • 75 Deng M, Scott MJ, Loughran P , et al. Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis. J Immunol 2013; 190 (10) 5152-5160
    CrossrefPubMedGoogle Scholar
  • 76 Hoque R, Vodovotz Y, Mehal W. Therapeutic strategies in inflammasome mediated diseases of the liver. J Hepatol 2013; 58 (5) 1047-1052
    CrossrefPubMedGoogle Scholar
  • 77 De Minicis S, Rychlicki C, Agostinelli L , et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 2014; 59 (5) 1738-1749
    CrossrefPubMedGoogle Scholar
  • 78 Fox JG, Feng Y, Theve EJ , et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 2010; 59 (1) 88-97
    CrossrefPubMedGoogle Scholar
  • 79 Yoshimoto S, Loo TM, Atarashi K , et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499 (7456) 97-101
    CrossrefPubMedGoogle Scholar
  • 80 Bindels LB, Porporato P, Dewulf EM , et al. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer 2012; 107 (8) 1337-1344
    CrossrefPubMedGoogle Scholar
  • 81 Barclay AR, Beattie LM, Weaver LT, Wilson DC. Systematic review: medical and nutritional interventions for the management of intestinal failure and its resultant complications in children. Aliment Pharmacol Ther 2011; 33 (2) 175-184
    CrossrefPubMedGoogle Scholar
  • 82 Li Z, Yang S, Lin H , et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37 (2) 343-350
    CrossrefPubMedGoogle Scholar
  • 83 Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49 (5) 821-830
    CrossrefPubMedGoogle Scholar
  • 84 Velayudham A, Dolganiuc A, Ellis M , et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49 (3) 989-997
    CrossrefPubMedGoogle Scholar
  • 85 Xu RY, Wan YP, Fang QY, Lu W, Cai W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr 2012; 50 (1) 72-77
    PubMedGoogle Scholar
  • 86 Wagnerberger S, Spruss A, Kanuri G , et al. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem 2013; 24 (3) 531-538
    CrossrefPubMedGoogle Scholar
  • 87 Okubo H, Sakoda H, Kushiyama A , et al. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol 2013; 305 (12) G911-G918
    CrossrefPubMedGoogle Scholar
  • 88 Ritze Y, Bárdos G, Claus A , et al. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS ONE 2014; 9 (1) e80169
    CrossrefPubMedGoogle Scholar
  • 89 Cani PD, Possemiers S, Van de Wiele T , et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58 (8) 1091-1103
    CrossrefPubMedGoogle Scholar
  • 90 Pachikian BD, Essaghir A, Demoulin JB , et al. Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. Mol Nutr Food Res 2013; 57 (2) 347-359
    CrossrefPubMedGoogle Scholar
  • 91 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol 2015; 7 (3) 559-565
    CrossrefPubMedGoogle Scholar
  • 92 Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007; (1) CD005165
    PubMedGoogle Scholar
  • 93 Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol 2015; 10: 889-902
    CrossrefPubMedGoogle Scholar
  • 94 Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol 2010; 16 (4) 403-410
    CrossrefPubMedGoogle Scholar
  • 95 Lata J, Jurankova J, Kopacova M, Vitek P. Probiotics in hepatology. World J Gastroenterol 2011; 17 (24) 2890-2896
    CrossrefPubMedGoogle Scholar
  • 96 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20 (42) 15518-15531
    Google Scholar
  • 97 Buss C, Valle-Tovo C, Miozzo S, Alves de Mattos A. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. Ann Hepatol 2014; 13 (5) 482-488
    PubMedGoogle Scholar
  • 98 Compare D, Coccoli P, Rocco A , et al. Gut—liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22 (6) 471-476
    CrossrefPubMedGoogle Scholar
  • 99 Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19 (40) 6911-6918
    CrossrefPubMedGoogle Scholar
  • 100 Malaguarnera M, Vacante M, Antic T , et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57 (2) 545-553
    Google Scholar
  • 101 Alisi A, Bedogni G, Baviera G , et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39 (11) 1276-1285
    CrossrefPubMedGoogle Scholar
  • 102 Vrieze A, Van Nood E, Holleman F , et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143 (4) 913-6.e7
    CrossrefPubMedGoogle Scholar